Tesamorelin is often discussed alongside shorter growth-hormone-releasing peptides, but its identity and clinical evidence need their own record. The most recognisable trials concern excess visceral fat in people with HIV receiving antiretroviral therapy. Reading those findings accurately means retaining both the molecular modification and the distinction between a specific fat compartment and general weight loss.
Retain the N-terminal modification
The official Egrifta WR description identifies tesamorelin as the 44-amino-acid human GRF sequence with a hexenoyl group attached at the N-terminal tyrosine. The medicine contains the acetate salt.FDA — Egrifta WR prescribing information, March 2025 (opens in a new tab)
That covalent modification is part of the molecule’s definition. Describing tesamorelin only as natural GHRH, or substituting a 29-residue fragment in a literature search, loses a material identity distinction.
The supplied 20 mg report describes a lyophilised 44-residue GHRH analogue and an LC-HRMS reference match. It does not print the complete sequence or terminal modification.Supplied Tesamorelin 20 mg report (opens in a new tab)
For a structure-to-study comparison, keep the public molecular description alongside the sample’s underlying reference specification. The analytical conclusion and the clinical literature do not independently fill every missing field in one another.
Read visceral-fat outcomes in their original setting
Falutz and colleagues’ 2007 trial randomised 412 people with HIV and abdominal fat accumulation to tesamorelin or placebo for 26 weeks. The primary outcome was percentage change in visceral adipose tissue measured by computed tomography.Falutz and colleagues — Metabolic effects of a growth hormone-releasing factor in patients with HIV (opens in a new tab)
Visceral fat decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group. The paper also reported lipid changes. More tesamorelin participants withdrew because of adverse events, although overall adverse-event frequencies did not differ significantly.Falutz and colleagues — Metabolic effects of a growth hormone-releasing factor in patients with HIV (opens in a new tab)
These findings concern a defined tissue compartment in a defined clinical population. A percentage change in visceral fat is not a percentage change in body weight and should not be displayed as though the two measures were interchangeable.
| Measure | Interpretive boundary |
|---|---|
| Visceral adipose tissue | An internal fat compartment measured by imaging |
| Body weight | A different whole-body measurement |
| Clinical cardiovascular events | An outcome that requires its own event data |
Improved lipid measurements may be relevant to later research, but they do not alone demonstrate fewer heart attacks or a longer life. That would require evidence on those outcomes.
Duration and withdrawal change the question
The 2008 extension report followed continued treatment and treatment withdrawal after the initial study period. Visceral-fat reduction was sustained during continued treatment, while fat reaccumulated after discontinuation.Falutz and colleagues — Long-term tesamorelin study extension (opens in a new tab)
That distinction matters when describing durability. A change maintained while an intervention continues is different from a lasting change after it stops.
Extension studies also need their own participant accounting. Readers should check who entered the extension, who changed groups and which comparison supports the follow-up statement, rather than treating every later measurement as a new independent trial.
Keep the clinical formulation separate from a catalogue material
The 2025 Egrifta WR label states that the product is not indicated for weight-loss management. It also explicitly distinguishes Egrifta WR from Egrifta SV: the two formulations are not substitutable.FDA — Egrifta WR prescribing information, March 2025 (opens in a new tab)
That is a useful reminder that even medicines sharing an active molecule can have formulation-specific requirements. A research vial cannot be assumed equivalent merely because its label also says tesamorelin.
The supplied certificate describes chemical testing of the submitted sample. It does not establish the sample’s equivalence to either medicine or reproduce the trial’s clinical findings.
For future research updates, record the exact material, the participant population, the fat compartment or other endpoint, and the observation period. Those fields keep a focused evidence base from becoming a broad and unsupported product promise.
Sources and further detail
- FDA — Egrifta WR prescribing information, March 2025 (opens in a new tab)
Official structure, indication-limit and formulation-distinction sections read. Preparation and administration instructions are not reproduced; no UK availability claim.
- Supplied Tesamorelin 20 mg report (opens in a new tab)
Complete supplied PDF read. Reference-based 44-residue identity statement retained without inventing a printed full structure or medicine equivalence.
- Falutz and colleagues — Metabolic effects of a growth hormone-releasing factor in patients with HIV (opens in a new tab)
Original 2007 abstract read for randomisation, CT endpoint, group changes and adverse-event withdrawals. Visceral-fat change is not represented as body-weight loss.
- Falutz and colleagues — Long-term tesamorelin study extension (opens in a new tab)
Original 2008 abstract read for continuation, rerandomisation and reaccumulation after discontinuation. Not counted as an independent replication of the initial trial.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.